Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) Operating Income (2023 - 2025)

Mangoceuticals (MGRX) has disclosed Operating Income for 3 consecutive years, with -$367739.0 as the latest value for Q4 2025.

  • Quarterly Operating Income rose 78.08% to -$367739.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$18.0 million through Dec 2025, down 126.2% year-over-year, with the annual reading at -$18.0 million for FY2025, 126.2% down from the prior year.
  • Operating Income hit -$367739.0 in Q4 2025 for Mangoceuticals, up from -$7.5 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $4.7 million in Q4 2023 to a low of -$7.5 million in Q3 2025.
  • Historically, Operating Income has averaged -$2.3 million across 3 years, with a median of -$2.2 million in 2023.
  • Biggest YoY gain for Operating Income was 78.08% in 2025; the steepest drop was 329.04% in 2025.
  • Year by year, Operating Income stood at $4.7 million in 2023, then tumbled by 135.57% to -$1.7 million in 2024, then skyrocketed by 78.08% to -$367739.0 in 2025.
  • Business Quant data shows Operating Income for MGRX at -$367739.0 in Q4 2025, -$7.5 million in Q3 2025, and -$5.3 million in Q2 2025.